URINARY MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) IN HIV PATIENTS IN RELATION TO DRUG THERAPY OF HIV AND RENAL FUNCTION | ||
| Journal of the Medical Research Institute | ||
| Article 2, Volume 37, Issue 1, September 2016, Pages 8-14 PDF (617.08 K) | ||
| DOI: 10.21608/jmalexu.2016.112119 | ||
| Abstract | ||
| Introduction: The relationship of the urinary Monocyte Chemoattractant Protein1 (MCP-1)/creatinine ratio to renal affection as manifested by decrease in eGFR and/or microalbuminuria was determined in patients with HIV infection. We compared urinary levels (normalized to urine creatinine) of MCP-1 in HIV infected patients receiving antiretroviral therapy (ART) to those not receiving ART. Fifty one HIV infected subjects were divided into two groups, group 1: not receiving ART, (N= 20), group 2: HIVinfected subjects receiving ART (N=31). Urinary MCP-1 was also determined in 20 healthy volunteers (group 3). Urinary MCP-1 levels were significantly higher in group 1 and 2 in comparison to group 3(p < br />=0.001).Both urinary MCP-1and urinary MCP-1/Cr ratio were negatively correlated with eGFR in HIV infected patients(r =-0.329, -0.347, and p = 0.018, 0.013 respectively). CD4+ T lymphocyte counts were negatively correlated with urinary MCP-1(r = -0.38 and p = 0.006) while urinary MCP-1/Cr ratio was positively correlated with uACR (r = 0.592, and p < br /><0.001). Levels of urinary MCP-1, uACR, urinary MCP-1/Cr. ratio and eGFR did not differ with the use of ART. Urinary ROC test to determine renal dysfunction in HIV infected patients(eGFR <60 ml/min), cutoff value of urinary MCP-1, urinary MCP-1/Cr. ratio and uACR were (>429 pg/ml, > 1.5(×10-6), > 456.9 mg/g Cr respectively) with sensitivity of (100%, 100%, 83.33% respectively)and specificity of (84.62 %,100 %, 93.33 % respectively) with a p value of (< 0.001, < 0.001, = 0.001 respectively). Conclusion: urinary MCP-1/Cr. ratio is sensitive and specific detector of renal affection and correlated to uACR in patients with HIV infection. Urinary MCP-1 did not differ in patients with HIV with the use of ART. | ||
|
Statistics Article View: 111 PDF Download: 348 |
||
